Hassan Alkhawam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hassan Alkhawam has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Darshan Patel
B Department of Medicine , Icahn School of Medicine at Mount Sinai , Elmhurst , NY , USA
1 shared publicationFeras Zaiem
D Mayo Evidence Based Practice Center - Mayo Clinic , Rochester , MN , USA
1 shared publication- Haidar Hajeh
University of California Riverside, Riverside, CA, USA
1 shared publication James Nguyen
B Department of Medicine , Icahn School of Medicine at Mount Sinai , Elmhurst , NY , USA
1 shared publication- Khaled M. Ziada
Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publication Maher Homsi
B Department of Medicine , Icahn School of Medicine at Mount Sinai , Elmhurst , NY , USA
1 shared publication
Latest Publications
- Open Access
- 30 January 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-9
Diagnosis and Management of Acute Coronary Syndrome Patients Without Obstructive Epicardial Stenosis
Purpose of Review: What is the pathophysiology and clinical findings as well as management of patients presenting with INOCA/MINOCA (Ischemia/Myocardial Infarction with Non-Obstructive Coronary Arteries). Recent Findings: INOCA/MINOCA has a complex pathophysiology. Summary: In this review article, we aim to summarize the complex pathophysiology and clinical diagnosis, and review the current management options.
- 30 January 2025
- Published by Springer Nature in Current Cardiology Reports
- Vol. 27 (1) , 1-9
Open AccessDiagnosis and Management of Acute Coronary Syndrome Patients Without Obstructive Epicardial Stenosis
Purpose of Review: What is the pathophysiology and clinical findings as well as management of patients presenting with INOCA/MINOCA (Ischemia/Myocardial Infarction with Non-Obstructive Coronary Arteries). Recent Findings: INOCA/MINOCA has a complex pathophysiology. Summary: In this review article, we aim to summarize the complex pathophysiology and clinical diagnosis, and review the current management options.
- 4 July 2017
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 72 (4) , 380-389
Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options
Amyloidosis covers a group of disorders that can manifest in virtually any organ system in the body and is thought to be secondary to misfolding of extracellular proteins with subsequent deposition in tissues. The precursor protein that is produced in excess defines the specific amyloid type. This requires histopathological confirmation using Congo-red dye with its characteristic demonstration of green birefringence under cross-polarized light. There are three main types of amyloidosis associated with cardiac involvement: light-chain (AL), familial or senile (ATTR), and secondary (AA) amyloidosis. The frequency of cardiac involvement and prognosis varies among each type. Amyloid cardiomyopathy commonly manifests as heart failure and the presenting features are usually dyspnoea, oedema, angina, pre-syncope and syncope. The diagnosis of cardiac amyloidosis is very hard and can easily be misdiagnosed. Although the imaging studies (such as echocardiography and cardiovascular magnetic resonance) may guide the diagnosis, tissue biopsy is needed for confirmation. Management of cardiac amyloidosis initially is to treat the underlying heart failure. Pacemaker implantation is usually required in patients with any conduction abnormalities. Transplantation is the next step with worsening heart failure. However, the aim of any treatment in amyloidosis, irrespective of type, is to prevent further deposition of amyloid while managing concurrent symptoms. In this manuscript, we will discuss the pathogenesis of cardiac amyloidosis, diagnostic methods and management options.
- 4 July 2017
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 72 (4) , 380-389
Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options
Amyloidosis covers a group of disorders that can manifest in virtually any organ system in the body and is thought to be secondary to misfolding of extracellular proteins with subsequent deposition in tissues. The precursor protein that is produced in excess defines the specific amyloid type. This requires histopathological confirmation using Congo-red dye with its characteristic demonstration of green birefringence under cross-polarized light. There are three main types of amyloidosis associated with cardiac involvement: light-chain (AL), familial or senile (ATTR), and secondary (AA) amyloidosis. The frequency of cardiac involvement and prognosis varies among each type. Amyloid cardiomyopathy commonly manifests as heart failure and the presenting features are usually dyspnoea, oedema, angina, pre-syncope and syncope. The diagnosis of cardiac amyloidosis is very hard and can easily be misdiagnosed. Although the imaging studies (such as echocardiography and cardiovascular magnetic resonance) may guide the diagnosis, tissue biopsy is needed for confirmation. Management of cardiac amyloidosis initially is to treat the underlying heart failure. Pacemaker implantation is usually required in patients with any conduction abnormalities. Transplantation is the next step with worsening heart failure. However, the aim of any treatment in amyloidosis, irrespective of type, is to prevent further deposition of amyloid while managing concurrent symptoms. In this manuscript, we will discuss the pathogenesis of cardiac amyloidosis, diagnostic methods and management options.